Curriculum Vitae ARUN K. KALRA, MD

Transcription

1 Curriculum Vitae ARUN K. KALRA, MD Office: CCARE California Cancer Associates in Research and Excellence Date St. Suite 103 Murrieta, California /2017 to current. Arun Kalra MD Inc. 09/2016 to 02/01/2017 Oncology Hematology Date St. Suite 103 Murrieta, California Affiliating Medical Centers: Loma Linda University Med CTR., Baxter RD Murrieta CA Inland Valley Hospital Inland Valley Dr. Wildomar CA Rancho Springs Medical Center Medical Center Dr. Murrieta CA Temecula Valley Hospital Temecula Parkway Temecula Ca Hemet Valley Medical Center 1117 E. Devonshire Avenue Hemet, California /2016 to present 03/01/2017 to present 03/01/2017 to present 02/2016 to present 10/2013 to Present Eisenhower Medical Center 07/2008 to 07/ Bob Hope Drive Rancho Mirage, California Desert Regional Medical Center 07/2008 to 03/01/ North Indian Canyon Drive Palm Springs, California P age

2 Education: PhD Candidacy in Cancer Pharmacology 03/1982 to 03/1984 State University of New York State University of New York 06/1982 to 06/1983 Master s Degree, Natural Sciences All India Institute of Medical Sciences 08/1971 to 12/1976 New Delhi, India MB,B.S. (M.D.) Undergraduate, Pre-Medical Degree 07/1970 to 06/1971 DAV College Jullundur City, Punjab, India Residency: Fellowships: Categorical Internal Medicine Residency 05/1977 to 06/1980 Wayne State University Medical Center Detroit, Michigan Medical Oncology Fellowship 07/1980 to 06/1982 Roswell Park Memorial Institute Senior Research Fellowship 07/1982 to 03/1984 Roswell Park Memorial Institute Board Certification: Diplomate- Internal Medicine- ABIM 09/1980 Diplomate- Medical Oncology- ABIM 09/1985 Interests All aspects of Medical Oncology, clinical and research, with special interest in: Personalized care of cancer patients-based on genetic analysis. Geriatric Oncology Value based care Human side of cancer Positions and Appointments: Hematology Oncology Specialists 02/2016 to 11/2016 Hemet Ca Apex Hematology/Oncology Medical Group 10/2013 to 02/2016 Hemet, California Desert Cancer Care, Inc. 07/2009 to 10/2013 Rancho Mirage, California 2 P age

3 Comprehensive Cancer Center 07/2008 to 06/2009 Palm Springs, California UCLA Westwood Hospital 01/2007 to 06/2008 Westwood, California Century City Doctor s Hospital 02/2006 to 06/2008 Century City, California Brotman Hospital 02/2006 to 07/2008 Culver City, California St. John s Hospital 02/2005 to 06/2008 Santa Monica, California UCLA Santa Monica Hospital 02/2006 to 06/2008 Santa Monica, California Sarcoma Oncology Center 09/2005 to 07/2008 Sant P. Chawla, MD Santa Monica, California Kaiser Permanente/CompHealth 06/2005 to 09/2005 West Los Angeles, California Sterling Rock Falls Clinic 05/ /2005 Sterling, Illinois Guthrie Medical Group 06/ /1990 Corning, New York VA Medical Center 01/1986 to 05/1990 Bath, New York Corning Medical and Surgical Associates 05/1984 to 06/1986 Corning, New York (later purchased by Guthrie Medical Group) Teaching Appointments Clinical Faculty Assistant Professor Internal Medicine Western University of Health Sciences/College of Osteopathic Medicine of the Pacific, California 08/2014 to present Voluntary Faculty 2006 to 2008 Department of Oncology University of Southern California Los Angeles, California Clinical Instructor 1984 to 1990 University of Rochester Medical School Rochester, New York 3 P age

4 Clinical Instructor 1980 to 1984 State University of New York Medical School Honors and Awards: Hospital Recognition 1984 to 1990 Bridge Builder Physician Recognition (three awards) Corning Hospital, Corning, New York Research Awards 1983 Gold Medal, Best Research Report Roswell Park Cancer Institute Medical School Standing 1971 to 1975 Rated among top 25% of students in the class Other Awards University Dean s Merit List Scholar, Punjab University 1971 National Science Talent Search Scholar, India National High School Boards Salutatorian, India 1969 Licenses: California Active Publications: 1. Taxane, Doxorubicin and Dexrazoxone in adjuvant chemotherapy of high-risk breast carcinoma. Programs and Proceedings, American Society of Clinical Oncologists Annual Meeting 2001, Abstract # Prolymphocytic Lymphoma in a patient with colon carcinoma. Program and proceedings American Society of Clinical Oncologists Annual Meeting 1993, Abstract # Familial Occurrence of Hairy Cell Leukemia in Two Brothers- A Case Report. Programs and proceedings American Society of Clinical Oncologists Annual Meeting Abstract #896 Research Experience: 2009 Sub-investigator- Novartis Pharmaceutical Corp: A Prospective, Randomized, Multi-Center, Three-arm Trial of the Continued Efficacy and Safety of Zometa in Patients with Documented Bone Metastases from Breast Cancer. Protocol # CZOL446E Sub-investigator- Gloucester Pharmaceuticals: A Phase II Trial of Romidepsin and Bortezomib for Patients with Multiple Myeloma Relapsed or Refractory Disease. Protocol # GPI P age

5 2009 Sub-investigator- Millennium Pharma: Phase IIIB, Randomized Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma who are not considered candidates with High Dose Chemotherapy and Autologous Stem Cell Transplantation. Velcade, Thalidomide and Dexamethasone (VTD) vs Velcade and Dexamethasone (VD) vs Velcade, Melphalan and Prednisone (VMP). Protocol # C Sub-investigator- Oncotherapeutics: A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients with Newly Diagnosed Multiple Myeloma. Protocol # X05272/DOIXILMMY Principle Investigator- Sanofi Aventis US, Inc: A Multinational, Randomized, Double-Blind Study Comparing the Efficacy of Aflibercept once every two (2) weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer. Protocol #EFC10547 (Vanilla) 2008/09 Sub-investigator- Amgen, Inc.: An Open-Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects with Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone. Protocol # /09 Sub-investigator- AOI Pharmacy, Inc: Sarcoma Alliance for Research Through Collaboration (SARC) Multicenter Trial: A Phase II Trial of Perifosine in Patients with Chemo-insensitive Sarcoma. Protocol #Perfosine# /09 Sub-investigator- SARC: A Multicenter, Open Label Single Arm Study of YONDELIS (trabectidin) for Subjects with Locally Advanced or Metastatic Soft Tissue Sarcoma who have relapsed or are refractory to standard of care treatment. Protocol #JOHNS006/ /09 Sub-investigator- Amgen, Inc: A Phase 1b/2 Study to Evaluate the Safety and Efficacy of AmG655 or AMG 479 in Combination with Gemcitabine and First-Line Therapy for Metastatic Pancreatic Cancer. Protocol # P age